Skip Navigation
Wilmer Eye Institute
Print This Page
Share this page: More

The Ocular Vasculogenesis and Angiogenesis Laboratory

The Ocular Vasculogenesis and Angiogenesis Laboratory

picture 1

The Ocular Vasculogenesis and Angiogenesis Laboratory at the Wilmer Eye Institute is the laboratory of Gerard "Jerry" Lutty, Ph.D., the G. Edward and G. Britton Durrell Professor of Ophthalmology.  Dr. Lutty's lab, with its highly skilled personnel, studies the development of blood vessels in the eye and how they change in diseases like retinopathy of prematurity (ROP; formerly called retolental fibroplasia or RLF), sickle cell and diabetic retinopathies, and age-related macular degeneration (AMD).  Dr. Lutty believes that a better understanding of the normal development and function of blood vessels will result in a greater understanding of what happens to them in disease processes like diabetes and AMD.

Ischemic retinopathies, one group of diseases which includes diabetic and sickle cell retinopathies, occur because blood vessels in the retina become blocked or occluded by blood cells sticking to the endothelial cells which line the blood vessel wall.  This change in blood flow causes the neural tissue in the retina to have insufficient nutrients and oxygen, i.e. become ischemic.  Ischemic retina releases substances that stimulate the growth of abnormal new blood vessels (neovascularization), which can leak and break and eventually can cause blindness.

Our lab examines the factors that stimulate new blood vessels, angiogenic factors, and naturally occurring inhibitors of angiogenesis, antiangiogenic factors.  The ultimate goal of the lab is to develop therapies to stop the blood vessels from being blocked in ischemic retinopathies and inhibit the growth of neovascularization.  This is being accomplished by merging nanotechnology with biological therapies.  These efforts are designed to build a new generation of therapeutics.

The therapeutics that are being developed utilize nanofabrication techniques to generate therapeutic nanoparticles that, when delivered to the eye, allow the tissues of the eye to essentially treat themselves only when needed.  The goal of these studies is to have the tissues generate their own therapeutics when needed and stop production when the condition is resolved.  These therapies will help reduce the need for repeated treatment and provide focused therapy, rather than treating the body with chemicals.

Dr. Pradeep Ramulu and Colleagues Study Relationship Between Vision Loss and Work Status - 7/18/2014

Wilmer Resident Receives Lindstrom Research Grant - 7/11/2014

Four Wilmer Researchers Receive BrightFocus Foundation Awards - 7/10/2014

Dr. Michael Repka Part of Team Researching Telemedicine and ROP - 6/27/2014

Dr. M. Valeria Canto-Soler and Colleagues Featured on WBAL-TV - 6/24/2014

Dr. M. Valeria Canto-Soler and Colleagues Use Human Stem Cells to Create Light-Sensitive Retina in a Dish - 6/10/2014

Wilmer's Division of Ocular Immunology Announces "Living With Uveitis" Support Group - 6/10/2014

Dr. Neil Bressler to Speak on Diabetic Retinopathy at National Eye Health Summit and Webcast - 6/10/2014

Dr. Donald Zack Receives a Research to Prevent Blindness Nelson Trust Award for Retinitis Pigmentosa - 6/9/2014

Dr. Michael Boland Leads Study on Effectiveness of Automated Telecommunication-Based Reminders on Adherence to Glaucoma Medication Dosing - 6/4/2014

Dr. Christina Prescott Discusses Summer Eye Protection on Fox 45 News - 6/1/2014

Dr. Jonathan Song Discusses Treatment Options for Pediatric Cataracts - 5/23/2014

Johns Hopkins' Jordan Green Discusses His Work at Wilmer's Translational Tissue Engineering Center - 5/21/2014

Longtime Wilmer Employee Lillie Alston Honored by Hopkins - 5/19/2014

Dr. Richard Semba: Diets Rich in Antioxidant Resveratrol Fail to Reduce Deaths, Heart Disease or Cancer - 5/12/2014

Dr. Neil Miller Explains Eye Twitching in The Wall Street Journal - 5/12/2014

Dr. Hendrik Scholl Receives ARVO Award - 5/7/2014


Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer